Document:

AGREEMENT

between

(1)   tbg Technologie-Beteiligungs-Gesellschaft mbH, with its registered seat in
      Bonn, registered in the commercial register of the local court Bonn under
      HRB 4990, Ludwig-Erhard-Platz 3, 53179 Bonn, Germany

                                                    hereafter referred to as tbg

(2)   DNAPrint genomics, Inc., 900 Cocoanut Avenue, Sarasota, Florida 34236, USA

                                          hereafter referred to as the Purchaser

         and

(3)   Biofrontera AG, with its registered seat in Leverkusen, registered in the
      commercial register of Cologne under HRB 49717, Hemmelrather Weg 201,
      51377 Leverkusen, Germany

                                         hereafter referred to as Biofrontera AG

Preamble:

Biofrontera AG is a German stock corporation. As of the date of the signing of
this agreement the share capital of Biofrontera AG amounts to EUR 1,862,869 and
is divided into 1,862,869 non-par value shares with a proportional amount of the
share capital of EUR 1.00 each. The shares are in registered form and not
certified; no single or multiple share certificates have been issued.

tbg holds 89,880 preferred shares class A in Biofrontera AG. Biofrontera AG
intends - with the consent of the holders of the preferred shares class A and B
and the consent of Biofrontera AG's general meeting - to convert all preferred
shares class A and B into common shares. All shares held by tbg - as of the date
of the signing of this agreement and after the conversion of the preferred
shares class A into common shares - are referred to as the tbg-Shares.

tbg entered into a participation agreement with the legal predecessor of
Biofrontera AG, the BioFrontera Pharmaceuticals GmbH, concerning the formation
of a silent partnership about DM 2 mill. dated 2/10 October 1998 (the
Participation Agreement I). Further, tbg entered into a participation agreement
with the legal predecessor of Biofrontera AG, BioFrontera Pharmaceutical GmbH
concerning the formation of another silent partnership about DM 3 mill. dated
2/10 October 1998 (the Participation Agreement II). Finally, tbg entered into a
third participation agreement with Biofrontera AG concerning the formation of a
third silent partnership about EUR 2,945,800 dated 8 January 2001 (the
Participation Agreement III). The Participation Agreement I, II and III are also
collectively referred to as the tbg-Participation Agreements. The
tbg-Participation Agreements are hereto attached as Annex 1, Annex 2 and Annex
3.

<PAGE>

I.    SALE AND ASSIGNMENT OF THE tbg-SHARES

1.    SALE AND ASSIGNMENT OF THE TBG-SHARES

1.1   tbg herewith irrevocably sells to the Purchaser the tbg-Shares including
      and together with all ancillary and associated rights of the tbg-Shares.
      The Purchaser herewith irrevocably accepts the sale of the tbg-Shares.

1.2   Subject to the payment of the Purchase Price, tbg herewith assigns
      irrevocably to the Purchaser the tbg-Shares including and together with
      all ancillary and associated rights of the tbg-Shares. The Purchaser
      accepts herewith the assignment of the tbg-Shares.

1.3   The right to all profits of Biofrontera AG of the current fiscal year and
      relating to all possible profits of Biofrontera AG incurred in previous
      fiscal years upon which as of the date of the assignment of the tbg-Shares
      the shareholders' meeting has not resolved upon shall be sold and assigned
      as well.

2.    Purchase Price

2.1   The purchase price for each Share shall be EUR 2.00. Hence, the total
      purchase price for the tbg-Shares is EUR 179,760 (Euro one hundred seventy
      nine thousand seven hundred sixty) (the Purchase Price).

2.2   The Purchase Price becomes due immediately after the signing of this
      Agreement. The Purchase Price is to be paid to tbg's bank account, account
      number 12 2089 4473 at KfW Bankengruppe Frankfurt, bank code 500 204 00.

                  2.3 Should any relevant tax authority or court rule that the
sale and assignment of the tbg-Shares set out in Clause 1 is taxable for VAT,
the Purchaser agrees to pay the VAT to tbg in accordance with such decision and
applicable law.

                  3. Warranty

      As of the date of the signing of this Agreement and as of the date on
      which the title to the tbg-Shares is transferred, tbg guarantees the
      correctness and completeness of the following statements by means of an
      independent guarantee promise within the meaning of section 311 para 1 of
      the German Civil Code, hereafter referred to as the BGB, which - according
      to the parties' expressed intentions - does not constitute a guarantee for
      the quality of the tbg-Shares within the meaning of sections 443 para 1
      alternative 1, 444 alternative 2 of the BGB but a promise which is made
      from the start only with the content restricted to the following:

      (a)   tbg has full legal title to the tbg-Shares. The tbg-Shares are not
            encumbered with third party's rights (except for obligations under
            the agreements referred to in Subclause 8.3).

      (b)   The tbg-Shares have been fully paid up and the capital contributions
            have not been paid back.

II.   SALE AND TRANSFER OF THE INTEREST IN SILENT PARTNERSHIPS

4.    Sale and transfer of the silent partnerships

4.1   tbg herewith irrevocably sells to the Purchaser all its interests in the
      silent partnerships with Biofrontera AG pursuant to the tbg-Participation
      Agreements, i.e. tbg sells any and all of its rights and obligations
      pursuant to or in connection with the tbg-Participation Agreements
      including any claims on profit sharing, interests and one-time
      considerations. The Purchaser accepts the sale.

<PAGE>

4.2   Subject to the payment of the S-Purchase Price tbg herewith irrevocably
      transfers to the Purchaser all its interests in the silent partnerships
      pursuant to the tbg-Participation Agreements, i.e. tbg transfers any and
      all of its rights and obligations pursuant to or in connection with the
      tbg-Participation Agreements including any claims on profit sharing,
      interests and one-time considerations. The Purchaser accepts the transfer.

4.3   The sale and transfer shall include any and all current and future,
      including contingent claims of tbg vis-a-vis Biofrontera AG under or in
      connection with the tbg-Participation Agreements.

4.4   Biofrontera AG consents to the transfers.

5.    S-Purchase Price

5.1   The purchase price for the sale and transfer of the interests in the
      silent partnerships pursuant to Clause 4 shall be EUR 1,320,240 (Euro one
      million three hundred twenty thousand two hundred forty) (the S-Purchase
      Price). The part purchase price for the interest in the silent partnership
      pursuant to the Participation Agreement I is EUR 245,300.59, for the
      interest in the silent partnership pursuant to the Participation Agreement
      II is EUR 368,082.91 (he S-II-Purchase Price) and for the interest in the
      silent partnership pursuant to the Participation Agreement III is EUR
      706,856.50.

5.2   The S-Purchase Price except for the S-II-Purchase Price becomes due
      without undue delay after the signing of this Agreement. The S-II-Purchase
      Price becomes due without undue delay after the consent requirement
      pursuant to Clause 8.4 has been fulfilled. The S-Purchase Price is to be
      paid to tbg's bank account as provided in Clause Error! Reference source
      not found..

5.3   Should any relevant authority or court rule that the sale and transfer of
      the interests in the silent partnerships pursuant to Clause 4 are taxable
      for VAT, the Purchaser agrees to pay the VAT to tbg in accordance with
      such decision and applicable law.

6.    Warranties regarding the silent partnerships

      As of the date of the signing of this Agreement and as of the date on
      which the title to the interests in the silent partnerships pursuant to
      Clause 4 is transferred, tbg guarantees the correctness and completeness
      of the following statements by means of an independent guarantee promise
      within the meaning of section 311 para 1 of the BGB, which - according to
      the parties' express intention - does not constitute a guarantee for the
      quality of the silent partnerships within the meaning of sections 443 para
      1 alternative 1, 444 alternative 2 of the BGB but a promise which is made
      from the start only with the content restricted to the following:

      (a)   Except for the tbg-Participation Agreements and the agreements
            listed in Sublcause 8.3 tbg has no further agreements with
            Biofrontera AG in relation to the silent partnerships and the
            tbg-Shares.

      (b)   Each of the tbg-Participation Agreements was validly entered into
            and has not been terminated by either party.

      (c)   tbg is the owner of each of the interests in the silent partnerships
            pursuant to the respective Participation Agreement I, II or III and
            has not disposed of any rights or claims which are sold and
            transferred pursuant to Clause 4.

<PAGE>

      (d)   tbg as silent partner has paid out to Biofrontera AG the capital
            contributions of DM 2 mill., DM 3 mill. and EUR 2,945,800
            respectively, these capital contributions have been transferred to
            Biofrontera AG's assets and have not been paid back in any way.

      (e)   No further warranties and guarantees are granted. In particular, tbg
            does not warrant Biofrontera AG's solvency and the value of the
            interests in the silent partnerships.

III.  JOINT PROVISIONS

7.    Confirmation

      The Purchaser herewith confirms that to the best of his knowledge the
      funds which will be transferred in fulfilment of the Purchase Price and
      the S-Purchase Price do not originate from one of the crimes listed in
      section 261 of the German Criminal Code.

8.    Consent Requirement/ Assignment of Contract

8.1   The parties acknowledge that the consent of Biofrontera AG pursuant to
      Clause 8 (3) of Biofrontera AG's articles of association to the assignment
      of the tbg-Shares has been given. A copy of the consent is attached as
      Annex 4.

8.2   The parties acknowledge that the general meeting of Biofrontera AG has
      consented to the transfer of the Participation Agreements. A copy of the
      consent is attached as Annex 5.

8.3   The parties acknowledge further that all parties to the "Shareholders'
      Agreement" dated 3 July 2003, the "Amendment to Shareholders' Agreement
      dated 3 July 2003" dated July 2003, the "Investment Agreement" dated 3
      July 2003 and the "Amendment to Investment Agreement dated 3 July" dated
      19 December 2003 have waived their rights of first refusal,
      tag-along-rights, blocking rights and further rights they might have in
      connection with the sale and transfer of the tbg-Shares by the tbg to the
      Purchaser. A copy of the Amendment to Shareholders' Agreement/Investment
      Agreement and Loan Agreement is attached as Annex 6 to this Agreement.

8.4   The parties to this Agreement acknowledge further that tbg needs the
      approval of the State Ministry of Economic Affairs and Employment for the
      transfer of the interest in the silent partnership pursuant to the
      Participation Agreement II. Thus, the parties agree that Clauses 4, Error!
      Reference source not found. and 6 shall only become effective with respect
      to the transfer of the interest in the silent partnership pursuant to the
      Participation Agreement II with the receipt of the consent of the State
      Ministry of Economic Affairs and Employment to the Purchaser.

9.    Final Provision

9.1   tbg and Biofrontera AG agree that there are no further claims or rights of
      tbg vis-a-vis Biofrontera AG in connection with the tbg-Shares or the
      interests in the silent partnerships as sold and transferred pursuant to
      Clause 4 if the sale and transfer of the tbg-Shares and the interests in
      the silent partnerships pursuant to Clause 4 has been completed.

9.2   Each party shall bear its own costs and expenses in connection with this
      Agreement, if any.

9.3   This Agreement is governed by and shall be construed in accordance with
      the German law. To the extent legally permissible, jurisdiction for all
      disputes arising out of, or in connection with this Agreement shall be
      with the competent courts in Frankfurt am Main, Germany.

9.4   The parties irrevocably waive their right to seek dissolution or to claim
      the nullity of this Agreement after it has been completed.

<PAGE>

9.5   Amendments and additions to this Agreement are only effective if made in
      writing, to the extent that notarisation is not required. The written form
      requirement also applies to any waivers, including a waiver of the written
      form requirement.

9.6   This Agreement may be executed in two or more counterparts, each of which
      shall be deemed to be an original, but all of which together shall
      constitute one and the same instrument.

9.7   Should individual terms of this Agreement be or become invalid or
      unenforceable or should this Agreement contain gaps, the validity of the
      remaining terms of the Agreement shall remain unaffected and in place of
      the invalid, unenforceable or missing terms a valid term on which the
      parties would have reasonably agreed, had they been aware at the signing
      of this Agreement that the relevant term was invalid, unenforceable or
      missing, shall be deemed to have been agreed upon. Should a term of this
      Agreement be or become invalid because of the scope of performance for
      which it provides then the agreed scope of performance shall be amended to
      correspond with the extent legally permitted.

9.8   The German version of this Agreement is conclusive.

                                   /s/ Michael Steinmetzer
      ------------------------     ---------------------------------------

      Ort/Datum                    tbg Technologie-Beteiligungs-Gesellschaft mbH

                                   /s/ Richard Gabriel
      ------------------------     ---------------------------------------

      Ort/Datum                    DNAPrint genomics, Inc.

                                   /s/ Herman Luebbert
      ------------------------     ---------------------------------------
      Ort/Datum                    Biofrontera AGAGREEMENT

      between

(1)   DNA Print genomics, Inc., 900 Cocoanut Avenue, Sarasota, FL 34236, USA

                                                    referred to as the Purchaser

and

(2)   Heidelberg Innovation BioScience Venture II GmbH & Co. KG, represented by
      Heidelberg Innovation Fonds Management GmbH, Neuenheimer Feld 581, 69120
      Heidelberg,

                                                           referred to as BSV II

(3)   Heidelberg Innovation Parallel-Beteiligungs GmbH & Co. KG a.A. represented
      by Heidelberg Innovation Fonds Management GmbH Neuenheimer Feld 581, 69120
      Heidelberg

                         referred to as HIPB and together with BSV II as Sellers

Preamble

Biofrontera AG is a German stock corporation registered with the commercial
register of the local court Cologne under HRB 49717, with its principle office
at Hemmelrather Weg 201, 51377 Leverkusen, Germany (the Biofrontera AG).

As of the signing of this agreement BSVII holds 314,178 preferred shares class B
and HIPB holds 169,173 preferred shares class B in Biofrontera AG. Further,
BSVII and/or HIPB intend to purchase 191,520 preferred shares class A and
231,587 preferred shares class B in Biofrontera AG from 3i Group Investments
Limited Partnership (the 3i). Biofrontera AG intends - with the consent of the
holders of the preferred shares class A and B and the consent of Biofrontera
AG's general meeting - to convert all preferred shares class A and B into common
shares. All shares held by BSVII and HIPB together, including shares acquired
from 3i, now and after the conversion of the preferred shares class A and B into
common shares are referred to as the Shares.

Biofrontera AG's management board with the consent of the supervisory board has
issued 60,000 convertible bonds with the nominal value of EUR 1.00 of each
convertible bond pursuant to the authorisation of Biofrontera AG's general
meeting dated 18 September 2004 (the Convertible Bonds). As of the signing of
this agreement, BSVII holds 22,000 Convertible Bonds and HIPB holds 5,500
Convertible Bonds. Further, BSVII and/or HIPB intend to purchase 15,000
Convertible Bonds from 3i. Each Convertible Bond entitles the bearer to convert
the Convertible Bond into one preferred share class B of Biofrontera AG.
Biofrontera AG intends - with the consent of the bearer of the Convertible Bonds
and the consent of Biofrontera AG's general meeting - to amend the conditions of
the Convertible Bonds so that each Convertible Bonds entitles the bearer to
convert one Convertible Bond into one common share of Biofrontera AG. All
Convertible Bonds held by BSVII and HIPB together, including Convertible Bonds
acquired from 3i, now and after the amendment to the conditions of the
Convertible Bonds are referred to as the H-Convertible Bonds.

                                       1
<PAGE>

On 18 September 2004 Biofrontera AG as borrower and 3i, BSVII, HIPB, TechnoMedia
Kapitalbeteiligungsgesellschaft Koln mbH and Professor Dr. Detlev Riesner as
lenders entered into a loan agreement, under which the lenders undertook to
grant EUR 1,200,000 to Biofrontera AG of which EUR 150,000 were only to be
granted to the Company at the sole discretion of the lenders (the 1. Loan
Agreement). Pursuant to the 1. Loan Agreement BSVII granted to Biofrontera AG a
loan in the amount of EUR 357,500 of which EUR 22,000 were paid in settlement of
the issue price of the H-Convertible Bonds issued to BSVII. Pursuant to the 1.
Loan Agreement HIPB granted to Biofrontera AG a loan in the amount of EUR
192,500 of which EUR 5,500 were paid in settlement of the issue price of the
H-Convertible Bonds issued to HIPB. Any and all rights and obligations of BSVII
under the 1. Loan Agreement (in particular its repayment claim of EUR 335,500)
are collectively referred to as the 1. BSVII-Loan. Any and all rights and
obligations of HIPB under the 1. Loan Agreement (in particular its repayment
claim of EUR 187,000) are collectively referred to as the HIPB-Loan. BSVII
and/or HIPB intend to purchase all rights and obligations of 3i under the 1.
Loan Agreement, in particular its repayment claim of EUR 247,500 vis-a-vis the
Company (3i's rights and obligations under the 1. Loan Agreement collectively
referred to as the 3i Loan).

On 13 March 2005 Biofrontera AG as borrower, BSVII, TechnoMedia
Kapitalbeteiligungsgesellschaft Koln GmbH and Professor Dr. Detlev Riesner as
lenders and the remaining shareholders of Biofrontera AG as of 13 March 2005
entered into loan agreement, under which the lenders undertook to grant EUR
550,000 to Biofrontera AG (the 2. Loan Agreement). Pursuant to the 2. Loan
Agreement BSVII granted to Biofrontera AG a loan in the amount of EUR 306,000.
Any and all rights and obligations of BSVII under the 2. Loan Agreement (in
particular its repayment claim of EUR 306,000) are collectively referred to as
the 2. BSVII-Loan. The 1. and 2. BSVII-Loan, the HIPB-Loan and the 3i Loan are
referred to as the Loans.

Each of the Sellers intends to waive vis-a-vis the shareholders of Biofrontera
AG its rights pursuant to the Loans, subject to the acceptance of Biofrontera
AG, and to subscribe for newly issued common shares in Biofrontera AG in return
for the waiver (the Conversion). The Sellers intend to subscribe for 57,767
newly issued common shares for the 1.BSVII-Loan, 52,449 newly issued common
shares for the 2.BSVII-Loan, 14,441 newly issued common shares for the HIPB-Loan
and 39,388 newly issued common shares for the 3i Loan (together the New Shares).

BSVII and HIPB are parties to a shareholders' agreement dated 5 July 2005 (the
Shareholders' Agreement), which is fully known to all of the parties hereto.
Words in capital letters not defined in this Agreement shall have the meaning
ascribed to them in the Shareholders' Agreement.

Biofrontera AG intends to issue convertible bonds up to the aggregated nominal
value of EUR 20,000,000. The corresponding shareholders' resolutions
substantially in the form of Error! Reference source not found. shall be passed
at a shareholders' meeting on 5 July 2005 (the P-Convertible Bonds).

1.    UNDERTAKING OF THE PURCHASER

1.1   Subject to Subclauses 1.4 to 1.7 the Purchaser undertakes vis-a-vis each
      of the Sellers to purchase the Shares, the New Shares and the
      H-Convertible Bonds from the Sellers under the terms and condition as set
      out substantially in Annex 1 (the Purchase Agreement). The parties agree
      that the final Purchase Agreement shall specify which and how many Shares,
      New Shares (or Loans, as the case may be) and H-Convertible Bonds will be
      sold and transferred by which of the Sellers and that each of the Sellers
      guarantees severally the warranties for the Shares, New Shares (or Loans,
      as the case may be) and the H-Convertible Bonds. If and to the extent that
      the Sellers did not effect the Conversion of their Loans as described in
      the Preamble and subject to Subclauses 1.4 to 1.7 the Purchaser undertakes
      vis-a-vis the Sellers to purchase the Loans for the purchase price of the
      New Shares.

1.2   If and to the extent that Shareholders exercise their right of first
      refusal pursuant to clause 6 of the Shareholders' Agreement and purchase
      some but not all parts of the Shares or New Shares the Purchaser
      undertakes - subject to Subclauses 1.4 to 1.7 - vis-a-vis each of the
      Sellers to purchase the remaining Shares or New Shares under the terms and
      conditions as set out substantially in the Purchase Agreement.

                                       2
<PAGE>

1.3   If and to the extent that B Investors exercise their Tag-Along Right
      pursuant to clause 7 of the Shareholders' Agreement the Purchaser
      undertakes - subject to Subclauses 1.4 to 1.7 - vis-a-vis each of the
      Sellers to purchase the number of shares of the Exercising B Investors as
      provided for in clause 7 of the Shareholders' Agreement instead of the
      relevant number of the Shares and New Shares and the remaining Shares and
      New Shares under the terms and conditions as set out substantially in the
      Purchase Agreement.

1.4   The purchase prices for the Shares, New Shares and the H-Convertible Bonds
      as stipulated in Annex 1 shall be adjusted if and to the extent that the
      purchase price per share, per Convertible Bond and per New Share
      subscribed for in connection with waiving the 3i Loan paid by the Sellers
      to 3i respectively is lower than set forth in Annex 1.

1.5   The Sellers shall only be entitled to exercise their rights pursuant to
      Subclauses 1.1, 1.2 and 1.3 if Biofrontera AG will not have issued
      P-Convertible Bonds in the aggregated amount of at least EUR 10,000,000 by
      31 December 2005.

1.6   The Sellers shall only be entitled to exercise their rights pursuant to
      Subclauses 1.1 to 1.5 jointly. Subject to Subclauses 1.2 and 1.3 the
      Sellers shall only be entitled to exercise their rights pursuant to
      Subclauses 1.1 to 1.5 with regard to all Shares, New Shares (or Loans, as
      the case may be) and all H-Convertible Bonds.

1.7   The Sellers must notify the Purchaser of the exercise of their rights
      pursuant to this Clause in written within the period of 1 January 2006
      until 14 January 2006 (inclusive). The receipt of the notice by the
      Purchaser is conclusive. The Purchaser acknowledges that such exercise is
      subject to the right of first refusal under clause 6 and the Tag-Along
      Right under clause 7 of the Shareholders' Agreement. The Purchase
      Agreement shall be entered into within two weeks of final determination as
      to what extent the aforesaid rights under the Shareholders' Agreement have
      been exercised, but in no event later than 12 weeks after the exercise of
      the Sellers' rights pursuant to Clause 1. Each party undertakes vis-a-vis
      each other to use all reasonable efforts to the effect, that the Purchase
      Agreement can be entered into in compliance with this Subclause.

2.    CONSIDERATION

      In consideration for the put-option pursuant to Clause 1, the Sellers
      grant to the Purchaser a call-option with regard to 60,000 preferred
      shares class A (acquired from 3i) held by them for the purchase price of
      EUR 2.00 per share (the Call-Option).

      (a)   The Call Option is exercisable for the time period from the date of
            the signing of this Agreement up until the earlier of the (i)
            exercise of the put-option pursuant to Clause 1 or (ii) the 28 day
            after the first day of trading following a stock exchange listing
            including an initial public offering of Biofrontera AG.

      (b)   The Purchaser acknowledges that the exercise of the Call-Option is
            subject to the right of first refusal under clause 6 and the
            Tag-Along Right under clause 7 of the Shareholders' Agreement and
            all other obligations entered into by the Sellers with regard to
            their Shares and New Shares under the Shareholders' Agreement.

      (c)   The Purchaser must notify the Sellers of the exercise of the
            Call-Option in written. The receipt of the notice by the Sellers is
            conclusive. The purchase agreement between the Purchaser and the
            Sellers shall be substantially in the form of the Purchase
            Agreement. Subclause 1.1 Sentence 2 applies (the
            Call-Option-Purchase Agreement). The Call-Option-Purchase Agreement
            shall be entered into within two weeks of final determination as to
            what extent the aforesaid rights under the Shareholders' Agreement
            have been exercised, but in no event later than 12 weeks after the
            exercise of the Purchaser's Call-Option. Each party undertakes
            vis-a-vis each other to use all reasonable efforts to the effect,
            that the Call-Option-Purchase Agreement can be entered into in
            compliance with this Clause.

                                       3
<PAGE>

3.    DURATION

      This Agreement lapses the later of

      (i)   the exercise of Sellers' rights under Clause 1 by or on14 January
            2006 and the completion of a Purchase Agreement in accordance with
            Subclause 1.7; or

      (ii)  - if the Sellers' right under Clause 1 has not been exercised by or
            on 14 January 2006 - the exercise of the Call-Option and the
            completion of a Call-Option-Purchase Agreement in accordance with
            Subclause 2(c).

4.    ASSIGMENT

      Neither party may assign its rights and obligations under this agreement
      without the written prior consent of the other parties.

5.    FINAL PROVISION

5.1   Each party shall bear its own costs and expenses in connection with this
      Agreement, if any.

5.2   BSVII and HIPB shall always act through BSVII who is herewith authorised
      by HIPB to act in the name and on behalf of HIPB and to act as receiving
      agent.

5.3   This Agreement is governed by and shall be construed in accordance with
      the German law. To the extent legally permissible, jurisdiction for all
      disputes arising out of, or in connection with this Agreement shall be
      with the competent courts in Frankfurt am Main, Germany.

5.4   The parties irrevocably waive their right to seek dissolution of this
      Agreement after it has been completed.

5.5   Amendments and additions to this Agreement are only effective if made in
      writing, to the extent that notarisation is not required. The written form
      requirement also applies to any waivers, including a waiver of the written
      form requirement.

5.6   This Agreement may be executed in two or more counterparts, each of which
      shall be deemed to be an original, but all of which together shall
      constitute one and the same instrument.

5.7   Should individual terms of this Agreement be or become invalid or
      unenforceable or should this Agreement contain gaps, the validity of the
      remaining terms of the Agreement shall remain unaffected and in place of
      the invalid, unenforceable or missing terms a valid term on which the
      parties would have reasonably agreed, had they been aware at the signing
      of this Agreement that the relevant term was invalid, unenforceable or
      missing, shall be deemed to have been agreed upon. Should a term of this
      Agreement be or become invalid because of the scope of performance for
      which it provides then the agreed scope of performance shall be amended to
      correspond with the extent legally permitted.

-------------------------------               ----------------------------------
         Place, date                          Place, date

                                              ----------------------------------
                                              Place, date

                                       4
<PAGE>

                                    ANNEX 1

                               PURCHASE AGREEMENT

between

(1)   Heidelberg Innovation BioScience Venture II GmbH & Co. KG, represented by
      Heidelberg Innovation Fonds Management GmbH, Neuenheimer Feld 581, 69120
      Heidelberg,

                                                            referred to as BSVII

(2)   Heidelberg Innovation Parallel-Beteiligungs GmbH & Co. KG a.A. represented
      by Heidelberg Innovation Fonds Management GmbH Neuenheimer Feld 581, 69120
      Heidelberg

                          referred to as HIPB and together with BSVII as Sellers

and

(3)   DNA Print genomics, Inc., 900 Cocoanut Avenue, Sarasota, FL 34236, USA

                                                    referred to as the Purchaser

Preamble:

Biofrontera AG is a German stock corporation registered with the commercial
register of the local court Cologne under HRB 49717, with its principle office
at Hemmelrather Weg 201, 51377 Leverkusen, Germany (the Biofrontera AG).

Words in capital letters shall have the meaning assigned to them in the
agreement between the Purchaser and the Sellers dated [o 2005 which is attached
hereto as Annex o.

The parties to this Agreement stipulate the following:

1.    Sale and Assignment of the Shares, the new Shares and H-Convertible Bonds

1.1   The Sellers herewith irrevocably sell, each with regard to the Shares, New
      Shares and H-Convertible Bonds held by it only, to the Purchaser the
      Shares, the New Shares and the H-Convertible Bonds including and together
      with all ancillary and associated rights of the Shares, the New Shares and
      the H-Convertible Bonds. The Purchaser irrevocably accepts herewith the
      sale of the Shares, the New Shares and the H-Convertible Bonds.

1.2   Subject to the payment of the Purchase Price, each of the Sellers assigns
      to the Purchaser the Shares, the New Shares and the H-Convertible Bonds
      held by it including and together with all ancillary and associated rights
      of the Shares, the New Shares and the H-Convertible Bonds and undertake to
      deliver the deeds of the H-Convertible Bonds. The Purchaser accepts
      herewith the assignment of the Shares, the New Shares and the Convertible
      Bonds.

                                       5
<PAGE>

1.3   The right to all results of Biofrontera AG of the current fiscal year and
      all possible profits of Biofrontera AG incurred in previous fiscal years
      which have not yet been distributed to the shareholders of Biofrontera AG
      shall be sold and assigned as well.

2.    Purchase Price

2.1   The purchase price for each Share or each New Share shall be EUR 3.00
      except for 191,520 Shares for which the purchase price shall be EUR 2.00
      per Shares (representing the number of preferred shares class A acquired
      by 3i). The purchase price for each H-Convertible Bond shall be EUR 0.30.
      Hence, the total purchase price for the Shares and the H-Convertible Bonds
      is EUR [o] (Euro [o]) (the Purchase Price).

2.2   The Purchase Price becomes due one week after all consent requirements
      pursuant to Clause 4 have been fulfilled and the Sellers have notified the
      Purchaser thereof. The Purchase Price is to be paid to BSVII's bank
      account, account number o at o bank code o. The Purchaser fulfils its
      payment obligation to HIPB by transferring the Purchase Price owed to HIPB
      to BSVII's account.

2.3   Should any relevant tax authority or court rule that the sales and
      assignments of the Shares, the New Shares and the H-Convertible Bonds set
      out in Clause 1 are taxable for VAT, the Purchaser agrees to pay the VAT
      to the Sellers in accordance with such decision and applicable law.

3.    Warranty

      As of the date of the signing of this Agreement and as of the date on
      which the title to the Shares, the New Shares and the H-Convertible Bonds
      is transferred to the Purchaser, each of the Sellers severally but not
      jointly, each with regard to the Shares, New Shares and H-Convertible
      Bonds held by it only, guarantee the correctness and completeness of the
      following statements by means of an independent guarantee promise within
      the meaning of section 311 para 1 of the German Civil Code, referred to as
      the BGB, which - according to the parties' express intention - does not
      constitute a guarantee for the quality of the Shares, the New Shares and
      the H-Convertible Bonds within the meaning of sections 443 para 1
      alternative 1, 444 alternative 2 of the BGB but a promise which is made
      from the start only with the content restricted to the following:

      (a)   The Sellers are the holders of the Shares, the New Shares and the
            H-Convertible Bonds. Neither the Shares, the New Shares nor the
            H-Convertible Bonds are encumbered with third party's rights (except
            for obligations under the agreements referred to in Schedule 1).

      (b)   The Shares and the New Shares have been fully paid up. Capital
            contributions with regard to the Shares and with regard to the New
            Shares have not been paid back to the Sellers. The issue price of
            the H-Convertible Bonds has been completely paid.

      (c)   No further warranties and guarantees are granted. In particular, the
            Sellers do not warrant Biofrontera AG's solvency.

4.    Consent Requirements/Assignment of Contract

4.1   The parties to this Agreement acknowledge that pursuant to Clause 8 (3) of
      Biofrontera AG's articles of association the assignments of the Shares and
      the New Shares require the consent of Biofrontera AG. Pursuant to Clause 8
      (3) sentence 2 of Biofrontera AG's articles of association Biofrontera
      AG's management board declares such consent on the basis of a
      shareholders' resolution. Further, Clause 8.2 of the terms of the
      H-Convertible Bonds provide that the transfer of the H-Convertible Bonds
      requires the consent of the Biofrontera AG.

                                       6
<PAGE>

4.2   Having regard to the preceding paragraph the parties agree that this
      Agreement shall become effective with the receipt of the consents of
      Biofrontera AG to the [Purchaser/to the Sellers] pursuant to Clause 4.1.

4.3   The parties of this Agreement agree to enter into an agreement stipulating
      the assignment of contracts to which the Sellers are parties, namely the
      shareholders' agreement.

5.    Final Provision

5.1   Each party shall bear its own costs and expenses in connection with this
      Agreement, if any.

5.2   BSVII and HIPB shall always act through BSVII who is herewith authorised
      by HIPB to act in the name and on behalf of HIPB and to act as its
      receiving agent.

5.3   This Agreement is governed by and shall be construed in accordance with
      the German law. To the extent legally permissible, jurisdiction for all
      disputes arising out of, or in connection with this Agreement shall be
      with the competent courts in Frankfurt am Main, Germany.

5.4   The parties irrevocably waive their right to seek dissolution of this
      Agreement after it has been completed.

5.5   Amendments and additions to this Agreement are only effective if made in
      writing, to the extent that notarisation is not required. The written form
      requirement also applies to any waivers, including a waiver of the written
      form requirement.

5.6   This Agreement may be executed in two or more counterparts, each of which
      shall be deemed to be an original, but all of which together shall
      constitute one and the same instrument.

5.7   Should individual terms of this Agreement be or become invalid or
      unenforceable or should this Agreement contain gaps, the validity of the
      remaining terms of the Agreement shall remain unaffected and in place of
      the invalid, unenforceable or missing terms a valid term on which the
      parties would have reasonably agreed, had they been aware at the signing
      of this Agreement that the relevant term was invalid, unenforceable or
      missing, shall be deemed to have been agreed upon. Should a term of this
      Agreement be or become invalid because of the scope of performance for
      which it provides then the agreed scope of performance shall be amended to
      correspond with the extent legally permitted.

                       /s/ Timo Hercegfi
-------------------    ---------------------------------------------------

place/date             Heidelberg Innovation BioScience Venture II GmbH & Co. KG

                       /s/ Timo Hercegfi
-------------------    --------------------------------------------------

place/date             Heidelberg Innovation Parallel-Beteiligungs GmbH & Co. KG

                       /s/ Richard Gabriel
-------------------    ------------------------------------

place/date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}]]